<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03811665</url>
  </required_header>
  <id_info>
    <org_study_id>RADSTER</org_study_id>
    <nct_id>NCT03811665</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiation Therapy Versus Radiofrequency Ablation for Small Renal Masses</brief_title>
  <acronym>SBRT vs RFA</acronym>
  <official_title>A Prospective Randomized Pilot Trial of Stereotactive Body Radiation Therapy Versus Radiofrequency Ablation for the Management of Small Renal Masses.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Joseph's Healthcare Hamilton</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Joseph's Healthcare Hamilton</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The execution of this study is pertinent to evaluating SBRT's short- and long-term efficacy
      and safety in the treatment of SRMs. This study will be the first to compare RFA and SBRT in
      the treatment of SRMs.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>12 Months</time_frame>
    <description>Failure will be defined as enhancement of ablated tissue greater than 10 Hounsfield units by CT contrast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 Months</time_frame>
    <description>Defined as post-procedural survival.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>12 Months</time_frame>
    <description>Defined as disease-free survival rate after a single procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease recurrence</measure>
    <time_frame>12 Months</time_frame>
    <description>Defined as disease recurrence rate after a single procedure, including positive biopsy result.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumour Size</measure>
    <time_frame>12 Months</time_frame>
    <description>Average percentage decrease in tumor size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function -eGFR</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in eGRF measured by mL/min/1.73m2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function - Serum Creatinine</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in serum creatinine level measured by umol/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function - Creatinine Clearance</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in creatinine clearance measured by ml/minute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication Rate</measure>
    <time_frame>12 Months</time_frame>
    <description>Intra and post intervention complication rates will be documented in terms of nausea, vomiting, diarrhea, hematuria, hemorrhage (requiring or not requiring transfusion), perinephric hematoma, ureteral strictures, loss of a renal unit, urinary leak, bleeding, fever and flulike symptoms, stomach/bowel ulceration, ureteropelvic junction obstruction, and upper pole hydrocalycosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients that experienced an adverse event.</measure>
    <time_frame>12 Months</time_frame>
    <description>Defined by any adverse event listed in the CTCAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score for quality of life</measure>
    <time_frame>12 Months</time_frame>
    <description>Defined by the generic EuroQol (EQ-5D) questionnaire that is a standardized measure of health. A scale of 0-100 (0 being the worse health, and 100 being the best health), is used for a patient to define their overall health and wellbeing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>Days</time_frame>
    <description>Duration of length of hospital stay (if applicable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost analysis</measure>
    <time_frame>12 Months</time_frame>
    <description>Defined by total cost of procedure and any associated related adverse events post procedure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Small Renal Masses (SRM)</condition>
  <arm_group>
    <arm_group_label>Stereotactic body radiation therapy (SBRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiofrequency Ablation (RFA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiofrequency Ablation</intervention_name>
    <description>RFA probe will create an ablation zone of a 1.0 cm diameter beyond the maximum CT-measured tumor diameter. The generator will modulate power up to 150 W in reach average ablative temperature of 105oC. Tumors will be treated for two cycles of 8 minutes duration each upon reaching target temperatures.</description>
    <arm_group_label>Radiofrequency Ablation (RFA)</arm_group_label>
    <other_name>RFA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactive body radiation therapy</intervention_name>
    <description>The Gross Tumour Volume (GTV) is defined as the visible tumour seen on the planning CT simulation. No clinical target volume (CTV) for microscopic disease is necessary. The internal target volume (ITV) accounts for changes in tumour position due to respiration, and is assessed on 4DCT. The planning target volume (PTV) will be a standard 0.5 cm around the ITV.</description>
    <arm_group_label>Stereotactic body radiation therapy (SBRT)</arm_group_label>
    <other_name>SBRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥18 years of age and capable of providing informed consent

          -  Patients scheduled for treatment of their SRM using SBRT or RFA

          -  Patients who received a biopsy of their SRM prior to their scheduled SBRT or RFA
             treatment

          -  Patients who are willing to have a biopsy 12 months post-procedure

          -  Patients with renal tumor(s) ≤ 4.0 cm

        Exclusion Criteria:

          -  Patients with large renal tumor(s)&gt;4.0 cm

          -  Patients who are unable to have a general anesthetic

          -  Patients who did not receive a biopsy of their SRM prior to their scheduled SBRT or
             RFA treatment

          -  Patients who are unable to comply with post-operative and/or follow-up protocol/phase
             of study

          -  Evidence of metastatic disease

          -  Uncorrectable bleeding diathesis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anil Kapoor, MD FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Joseph's Healthcare Hamilton</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Camilla Tajzler, BA, CCRA</last_name>
    <phone>905-522-1155</phone>
    <phone_ext>35876</phone_ext>
    <email>tajzlec@mcmaster.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anil Kapoor, MD, FRCSC</last_name>
    <phone>905-522-1155</phone>
    <phone_ext>33218</phone_ext>
    <email>akapoor@mcmaster.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>McMaster Institute of Urology - St. Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Kapoor, MD</last_name>
      <phone>905.5226536</phone>
      <email>kapoor4@mcmaster.ca</email>
    </contact>
    <contact_backup>
      <last_name>Camilla Tajzler, BA, CCRA</last_name>
      <phone>905-522-1155</phone>
      <phone_ext>35876</phone_ext>
      <email>tajzlec@mcmaster.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Anil Kapoor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edward Matsumoto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 13, 2018</study_first_submitted>
  <study_first_submitted_qc>January 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2019</study_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Joseph's Healthcare Hamilton</investigator_affiliation>
    <investigator_full_name>Anil Kapoor</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

